T1	PROC 44 65	Ensayo de dosis única
T2	PROC 1115 1141	retirada de vías centrales
#1	AnnotatorNotes T2	C0458124; Removal of central venous line; Therapeutic or Preventive Procedure
T3	PROC 1539 1557	Cifra de plaquetas
T4	DISO 172 181	trombosis
#2	AnnotatorNotes T4	C0040053; Thrombosis; Pathologic Function
T5	DISO 203 211	coágulos
#3	AnnotatorNotes T5	C0302148; Blood Clot; Pathologic Function
T6	PROC 234 255	Ensayo de dosis única
T7	CHEM 287 298	rivaroxaban
#4	AnnotatorNotes T7	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T8	DISO 369 378	trombosis
#5	AnnotatorNotes T8	C0040053; Thrombosis; Pathologic Function
T9	DISO 455 464	Trombosis
#6	AnnotatorNotes T9	C0040053; Thrombosis; Pathologic Function
T10	PROC 560 586	tratamiento anticoagulante
#7	AnnotatorNotes T10	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T11	CHEM 653 660	fármaco
#8	AnnotatorNotes T11	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T12	PROC 676 697	Tiempo de protrombina
#9	AnnotatorNotes T12	C0033707; Prothrombin time assay; Laboratory Procedure
T13	PROC 866 890	consentimiento informado
#10	AnnotatorNotes T13	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T14	PROC 705 746	tiempo de tromboplastina parcial activada
#11	AnnotatorNotes T14	C0030605; Activated Partial Thromboplastin Time measurement; Laboratory Procedure
T15	PROC 748 752	TTPa
#12	AnnotatorNotes T15	C0030605; Activated Partial Thromboplastin Time measurement; Laboratory Procedure
T16	CHEM 828 835	fármaco
#13	AnnotatorNotes T16	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T17	DISO 961 972	Hemorragias
#14	AnnotatorNotes T17	C0019080; Hemorrhage; Pathologic Function
T18	DISO 1001 1012	hemorragias
#15	AnnotatorNotes T18	C0019080; Hemorrhage; Pathologic Function
T19	PROC 1034 1060	tratamiento anticoagulante
#16	AnnotatorNotes T19	C0150457; Anticoagulant therapy; Therapeutic or Preventive Procedure
T20	PROC 1207 1237	Filtración glomerular estimada
T21	DISO 1272 1283	Hepatopatía
#17	AnnotatorNotes T21	C0023895; Liver diseases; Disease or Syndrome
T22	DISO 1296 1309	coagulopatías
#18	AnnotatorNotes T22	C0005779; Blood Coagulation Disorders; Disease or Syndrome
T23	DISO 1336 1346	hemorragia
#19	AnnotatorNotes T23	C0019080; Hemorrhage; Pathologic Function
T24	PROC 1373 1397	alanina aminotransferasa
#20	AnnotatorNotes T24	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T25	PROC 1064 1088	Procedimientos invasivos
#21	AnnotatorNotes T25	C4048276; Invasive procedure; Therapeutic or Preventive Procedure
T26	PROC 1459 1476	bilirrubina total
#22	AnnotatorNotes T26	C0201913; Bilirubin, total measurement; Laboratory Procedure
T27	PROC 1495 1514	bilirrubina directa
#23	AnnotatorNotes T27	C0201916; Bilirubin, direct measurement; Laboratory Procedure
T28	ANAT 1548 1557	plaquetas
#24	AnnotatorNotes T28	C0005821; Blood Platelets; Cell
T29	DISO 1578 1590	Hipertensión
#25	AnnotatorNotes T29	C0020538; Hypertensive disease; Disease or Syndrome
T30	CHEM 1702 1769	inhibidores potentes de la isoenzima CYP3A4 y de la glucoproteína P
T31	PROC 1239 1242	FGe
#26	AnnotatorNotes T31	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
T32	CHEM 1791 1858	inhibidores de la proteasa del virus de la inmunodeficiencia humana
#27	AnnotatorNotes T32	C0162714; HIV Protease Inhibitors; Pharmacologic Substance
T33	CHEM 1876 1898	antimicóticos azólicos
#28	AnnotatorNotes T33	C0360363; Azole antifungal; Organic Chemical · Pharmacologic Substance
T34	CHEM 1900 1911	ketoconazol
#29	AnnotatorNotes T34	C0022625; ketoconazole; Organic Chemical · Pharmacologic Substance
T35	CHEM 1913 1924	itraconazol
#30	AnnotatorNotes T35	C0064113; itraconazole; Organic Chemical · Pharmacologic Substance
T36	CHEM 1926 1937	voriconazol
#31	AnnotatorNotes T36	C0393080; voriconazole; Organic Chemical · Pharmacologic Substance
T37	CHEM 1940 1951	posaconazol
#32	AnnotatorNotes T37	C0936148; posaconazole; Organic Chemical · Pharmacologic Substance
T38	CHEM 2002 2012	fluconazol
#33	AnnotatorNotes T38	C0016277; fluconazole; Organic Chemical · Pharmacologic Substance
T39	CHEM 2037 2079	inductores potentes de la isoenzima CYP3A4
T40	CHEM 2094 2105	rifampicina
#34	AnnotatorNotes T40	C0035608; rifampin; Antibiotic · Organic Chemical
T41	CHEM 2107 2117	rifabutina
#35	AnnotatorNotes T41	C0140575; rifabutin; Antibiotic · Organic Chemical
T42	CHEM 2119 2131	fenobarbital
#36	AnnotatorNotes T42	C0031412; phenobarbital; Organic Chemical · Pharmacologic Substance
T43	CHEM 2133 2142	fenitoína
#37	AnnotatorNotes T43	C0031507; phenytoin; Organic Chemical · Pharmacologic Substance
T44	CHEM 2145 2158	carbamazepina
#38	AnnotatorNotes T44	C0006949; carbamazepine; Organic Chemical · Pharmacologic Substance
T45	PROC 2195 2209	procedimientos
#39	AnnotatorNotes T45	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure | C0184661; Interventional procedure; Therapeutic or Preventive Procedure
T46	DISO 2226 2243	Hipersensibilidad
#40	AnnotatorNotes T46	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T47	CHEM 2246 2257	Rivaroxaban
#41	AnnotatorNotes T47	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T48	CHEM 2333 2344	Rivaroxaban
#42	AnnotatorNotes T48	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T49	PROC 2399 2410	tratamiento
#43	AnnotatorNotes T49	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T50	CHEM 79 90	rivaroxaban
#44	AnnotatorNotes T50	C1739768; rivaroxaban; Organic Chemical · Pharmacologic Substance
T51	DISO 408 429	Coagulación sanguínea
T52	ANAT 420 429	sanguínea
#45	AnnotatorNotes T52	C0005767; Blood; Body Substance
T53	CHEM 572 586	anticoagulante
#46	AnnotatorNotes T53	C0003280; Anticoagulants; Pharmacologic Substance
T54	PROC 634 660	administración del fármaco
#47	AnnotatorNotes T54	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T55	CHEM 686 697	protrombina
#48	AnnotatorNotes T55	C0033706; prothrombin; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T56	PROC 699 701	TP
#49	AnnotatorNotes T56	C0033707; Prothrombin time assay; Laboratory Procedure
T57	CHEM 715 729	tromboplastina
#50	AnnotatorNotes T57	C0040048; Thromboplastin; Amino Acid, Peptide, or Protein · Immunologic Factor
T58	PROC 809 835	administración del fármaco
#51	AnnotatorNotes T58	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T59	CHEM 1046 1060	anticoagulante
#52	AnnotatorNotes T59	C0003280; Anticoagulants; Pharmacologic Substance
T60	PROC 1171 1185	administración
#53	AnnotatorNotes T60	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T61	PROC 1399 1402	ALT
#54	AnnotatorNotes T61	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T62	CHEM 1459 1470	bilirrubina
#55	AnnotatorNotes T62	C0005437; Bilirubin; Biologically Active Substance · Organic Chemical
T63	CHEM 1495 1506	bilirrubina
#56	AnnotatorNotes T63	C0005437; Bilirubin; Biologically Active Substance · Organic Chemical
T64	PROC 1609 1648	presión arterial sistólica o diastólica
T65	CHEM 2297 2321	fármaco en investigación
#57	AnnotatorNotes T65	C0013230; Investigational New Drugs; Pharmacologic Substance
T66	Date 12 16	2015
T67	Dose 54 65	dosis única
T68	Form 94 131	polvo seco para diluido en suspensión
T70	Route 132 136	oral
#58	AnnotatorNotes T70	C1527415; Oral Route of Drug administration; Functional Concept
T71	LIVB 141 146	niños
#59	AnnotatorNotes T71	C0008059; Child; Age Group
T72	Age 147 167	de 6 meses a 12 años
T74	Dose 244 255	dosis única
T75	Form 302 328	polvo seco para suspensión
T77	Route 329 333	oral
#60	AnnotatorNotes T77	C1527415; Oral Route of Drug administration; Functional Concept
T78	LIVB 338 343	niños
#61	AnnotatorNotes T78	C0008059; Child; Age Group
T79	Age 344 364	de 6 meses a 12 años
T82	LIVB 494 499	Niños
#62	AnnotatorNotes T82	C0008059; Child; Age Group
T83	Age 503 535	entre 6 meses y menos de 12 años
T85	Duration 587 603	al menos 10 días
T87	Duration 766 777	los 10 días
T89	LIVB 927 931	niño
#63	AnnotatorNotes T89	C0008059; Child; Age Group
T91	Duration 1145 1157	las 24 horas
T92	Dose 1192 1203	dosis única
T94	Spec_cue 1326 1335	riesgo de
T95	PHYS 1609 1625	presión arterial
#64	AnnotatorNotes T95	C0005823; Blood Pressure; Organism Function
T97	LIVB 1822 1858	virus de la inmunodeficiencia humana
#65	AnnotatorNotes T97	C0019682; HIV; Virus
T98	Neg_cue 2162 2176	Incapacidad de
T100	Duration 2376 2387	los 30 días
T73	Spec_cue 983 989	riesgo
T76	PHYS 1207 1228	Filtración glomerular
#66	AnnotatorNotes T76	C0232809; Glomerular filtration; Organ or Tissue Function
T69	Neg_cue 2322 2332	distinto a
T80	DEVI 2354 2372	producto sanitario
#67	AnnotatorNotes T80	C0025080; Medical Device; Medical Device
T81	Observation 2177 2209	colaborar con los procedimientos
#68	AnnotatorNotes T81	C0517036; Cooperates with procedures; Finding
T84	DEVI 1127 1141	vías centrales
#69	AnnotatorNotes T84	C1145640; Central venous catheter, device; Medical Device
T86	ANAT 1218 1228	glomerular
#70	AnnotatorNotes T86	C0022663; Kidney Glomerulus; Body Part, Organ, or Organ Component | C1284485; Entire glomerulus; Body Part, Organ, or Organ Component
A1	Population_data T71 Age
A2	Population_data T78 Age
A3	Population_data T82 Age
A6	Population_data T89 Age
A7	Assertion T18 Speculated
A8	Assertion T23 Speculated
A4	Assertion T48 Negated
A5	Status T4 History_of
A10	Status T5 History_of
A11	Status T8 History_of
A12	Assertion T19 Contraindicated
A13	Assertion T59 Contraindicated
A9	Status T46 History_of
A14	Assertion T81 Negated
#71	AnnotatorNotes T51	C0302148; Blood Clot; Pathologic Function
#72	AnnotatorNotes T20	C3811844; Estimated Glomerular Filtration Rate; Laboratory Procedure
#73	AnnotatorNotes T3	C0032181; Platelet Count measurement; Laboratory Procedure
#74	AnnotatorNotes T64	C1305849; Diastolic blood pressure measurement; Diagnostic Procedure | C1306620; Systolic blood pressure measurement; Diagnostic Procedure
R1	Speculation Arg1:T73 Arg2:T18	
R2	Speculation Arg1:T94 Arg2:T23	
T88	Quantifier_or_Qualifier 1347 1369	clínicamente relevante
A15	Assertion T88 Speculated
R3	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T88	
R4	Negation Arg1:T98 Arg2:T81	
R5	Negation Arg1:T69 Arg2:T48	
R6	Has_Dose_or_Strength Arg1:T50 Arg2:T67	
R7	Has_Dose_or_Strength Arg1:T7 Arg2:T74	
R8	Has_Drug_Form Arg1:T7 Arg2:T75	
R9	Has_Drug_Form Arg1:T50 Arg2:T68	
R10	Has_Route_or_Mode Arg1:T50 Arg2:T70	
R11	Has_Route_or_Mode Arg1:T7 Arg2:T77	
R12	Experiences Arg1:T78 Arg2:T7	
R13	Experiences Arg1:T71 Arg2:T50	
R14	Has_Age Arg1:T71 Arg2:T72	
R15	Has_Age Arg1:T78 Arg2:T79	
R16	Experiences Arg1:T71 Arg2:T4	
R17	Experiences Arg1:T78 Arg2:T8	
R18	Experiences Arg1:T71 Arg2:T5	
R20	Has_Age Arg1:T82 Arg2:T83	
R21	Experiences Arg1:T82 Arg2:T10	
R22	Has_Duration_or_Interval Arg1:T53 Arg2:T85	
R23	Used_for Arg1:T53 Arg2:T10	
R24	Before Arg1:T10 Arg2:T54	
R25	Used_for Arg1:T11 Arg2:T54	
R26	Experiences Arg1:T82 Arg2:T54	
T90	Result_or_Value 754 762	normales
#75	AnnotatorNotes T90	C0586624; Normal laboratory finding; Finding
R27	Has_Result_or_Value Arg1:T15 Arg2:T90	
R28	Has_Result_or_Value Arg1:T14 Arg2:T90	
R29	Has_Result_or_Value Arg1:T56 Arg2:T90	
R30	Has_Result_or_Value Arg1:T12 Arg2:T90	
R31	Overlap Arg1:T15 Arg2:T87	
R32	Overlap Arg1:T14 Arg2:T87	
R33	Overlap Arg1:T56 Arg2:T87	
R34	Overlap Arg1:T12 Arg2:T87	
R35	Before Arg1:T12 Arg2:T58	
R36	Before Arg1:T56 Arg2:T58	
R37	Before Arg1:T14 Arg2:T58	
R38	Before Arg1:T15 Arg2:T58	
R39	Used_for Arg1:T16 Arg2:T58	
T93	Quantifier_or_Qualifier 973 980	activas
#76	AnnotatorNotes T93	C0205177; Active; Qualitative Concept
R40	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T93	
R41	Used_for Arg1:T59 Arg2:T19	
R42	Used_for Arg1:T84 Arg2:T2	
R43	Overlap Arg1:T2 Arg2:T91	
R44	Overlap Arg1:T25 Arg2:T91	
R45	Before Arg1:T25 Arg2:T60	
R46	Before Arg1:T2 Arg2:T60	
R47	Has_Dose_or_Strength Arg1:T60 Arg2:T92	
R48	Location_of Arg1:T86 Arg2:T76	
R49	Location_of Arg1:T86 Arg2:T20	
R50	Location_of Arg1:T86 Arg2:T31	
T96	Result_or_Value 1244 1268	menor a 30 mL/min/1,73m2
R51	Has_Result_or_Value Arg1:T31 Arg2:T96	
R52	Has_Result_or_Value Arg1:T20 Arg2:T96	
R53	Overlap Arg1:T21 Arg2:T22	
R54	Before Arg1:T22 Arg2:T23	
T99	Result_or_Value 1404 1455	mayor 5 × el límite superior de la normalidad (LSN)
R55	Has_Result_or_Value Arg1:T24 Arg2:T99	
R56	Has_Result_or_Value Arg1:T61 Arg2:T99	
T101	Result_or_Value 1477 1490	mayor 2 × LSN
R57	Has_Result_or_Value Arg1:T26 Arg2:T101	
T102	Result_or_Value 1515 1535	mayor 20 % del total
R58	Has_Result_or_Value Arg1:T27 Arg2:T102	
T103	Result_or_Value 1558 1574	menor 50 × 109/L
R63	Has_Result_or_Value Arg1:T3 Arg2:T103	
T104	Result_or_Value 1649 1678	mayor al percentil 95 de edad
R64	Has_Result_or_Value Arg1:T64 Arg2:T104	
T105	Quantifier_or_Qualifier 1686 1698	concomitante
#77	AnnotatorNotes T105	C0521115; Simultaneous; Temporal Concept
R65	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T105	
R66	Has_Quantifier_or_Qualifier Arg1:T32 Arg2:T105	
R67	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T105	
T107	Quantifier_or_Qualifier 2021 2033	concomitante
#79	AnnotatorNotes T107	C0205373; Systemic; Functional Concept
R68	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T107	
R69	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T105	
R70	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T105	
R71	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T105	
R72	Has_Quantifier_or_Qualifier Arg1:T37 Arg2:T105	
R73	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T107	
R74	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T107	
R75	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T107	
R76	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T107	
R77	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T107	
R78	Causes Arg1:T47 Arg2:T46	
T108	Observation 2262 2289	Participación en un estudio
#80	AnnotatorNotes T108	C1278516; Patient participation status; Finding (?)
R79	Has_Duration_or_Interval Arg1:T108 Arg2:T100	
R80	Before Arg1:T108 Arg2:T49	
R81	Has_Duration_or_Interval Arg1:T80 Arg2:T100	
R82	Has_Duration_or_Interval Arg1:T65 Arg2:T100	
R83	Before Arg1:T80 Arg2:T49	
R84	Before Arg1:T65 Arg2:T49	
T109	ANAT 1617 1625	arterial
#81	AnnotatorNotes T109	C0003842; Arteries; Body Part, Organ, or Organ Component | C1285085; Entire artery; Body Part, Organ, or Organ Component
R19	Location_of Arg1:T109 Arg2:T95	
R85	Location_of Arg1:T109 Arg2:T64	
T110	Quantifier_or_Qualifier 990 997	elevado
R89	Has_Quantifier_or_Qualifier Arg1:T73 Arg2:T110	
T111	Quantifier_or_Qualifier 546 556	finalizado
R90	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T111	
R91	Has_Duration_or_Interval Arg1:T90 Arg2:T87	
T112	Route 1971 1986	forma sistémica
R94	Has_Route_or_Mode Arg1:T37 Arg2:T112	
R95	Has_Route_or_Mode Arg1:T36 Arg2:T112	
R96	Has_Route_or_Mode Arg1:T35 Arg2:T112	
R97	Has_Route_or_Mode Arg1:T34 Arg2:T112	
R98	Has_Route_or_Mode Arg1:T33 Arg2:T112	
R99	Has_Route_or_Mode Arg1:T32 Arg2:T112	
R100	Has_Route_or_Mode Arg1:T30 Arg2:T112	
R101	Has_Route_or_Mode Arg1:T38 Arg2:T112	
T113	CONC 1988 1998	se permite
T106	Observation 910 922	asentimiento
#78	AnnotatorNotes T106	C1302239; Patient consented to clinical trial; Finding (?)
R103	Experiences Arg1:T89 Arg2:T106	
#82	AnnotatorNotes T30	C3830624; CYP3A4 Inhibitor; Chemical Viewed Structurally (?) | C3898062; P-glycoprotein Inhibitor; Organic Chemical · Pharmacologic Substance
#83	AnnotatorNotes T39	C3850041; Cytochrome P-450 CYP3A4 Inducers; Pharmacologic Substance (?)
#84	AnnotatorNotes T111	C1272693; Ended - status; Qualitative Concept
#85	AnnotatorNotes T110	C0205250; High; Qualitative Concept
R59	Overlap Arg1:T21 Arg2:T24	
R60	Overlap Arg1:T21 Arg2:T61	
R61	Overlap Arg1:T21 Arg2:T26	
R62	Overlap Arg1:T21 Arg2:T27	
#86	AnnotatorNotes T88	C5209294; Clinical relevance; Intellectual Product
R86	Speculation Arg1:T94 Arg2:T88	
#87	AnnotatorNotes T68	C1273622; Powder for Oral Suspension; Biomedical or Dental Material (?) ['dry powder formulation for oral suspension']
#88	AnnotatorNotes T75	C1273622; Powder for Oral Suspension; Biomedical or Dental Material (?) ['dry powder formulation for oral suspension']
#89	AnnotatorNotes T112	C0205373; Systemic; Functional Concept
A16	Experiencer T71 Patient
A17	Experiencer T78 Patient
A18	Experiencer T82 Patient
A19	Experiencer T89 Patient
A20	Status T25 Future
A21	Status T2 Future
A22	Assertion T112 Hypothetical
T114	Observation 983 1000	riesgo elevado de
#90	AnnotatorNotes T114	C0332167; High risk of; Finding
